# IISPV – Accreditation ISCIII IISPV Strategic Plan 2021-2025

Barcelona, May 2022



# Table of contents

00 Introduction	<u>04</u>
01 Internal and External Analysis - SWOT	<u>14</u>
02 CAME Analysis	<u>17</u>
03 Vision	<u>18</u>
04 Strategic Map	<u>19</u>

Pere Virgili Institute for Health Research (IISPV)



Pere Virgili Institute for Health Research (IISPV) is a multidisciplinary and translational biomedical research centre focused clinical, on basic, epidemiological and health services research. It is the result of a partnership between groups from Hospital Universitari Sant Joan de Reus, Hospital Universitari Joan XXIII de Tarragona, Grup Pere Mata, Hospital de Tortosa Verge de la Cinta and Universitat Rovira i Virgili (URV).

Hospital Universitari Sant Joan REUS **HJ**23 Hospital Universitari Joan XXIII ICS Camp de Tarragona HTVC Hospital de Tortosa Verge de la Cinta **UNIVERSITAT ROVIRA i VIRGILI** 

# Scientific structure of the IISPV, Areas and Groups (1/4)

#### **IISPV Scientific Structure::**

IISPV currently has 4 Areas: Nutrition and Metabolism, Health and Environment, Neurosciences and Mental Health and Clinical Groups. These areas include several research groups.

#### Area 1. Nutrition & Metabolism

Grupo de investigación en enfermedades inflamatorias intestinales

- IBODI

Responsable Carolina Serena Perelló EMERGING GROUP

OBESITY. Obesity and Metabolic Surgery Research Group

Responsible Daniel Del Castillo Déjardin CONSOLIDATED Cardiology Research Group - RISCAT Responsible Alfredo Bardají CONSOLIDATED

DIAMET. Diabetes and metabolic associated diseases research group

Responsible Sonia Fernández-Veledo, Joan Josep Vendrell Ortega CONSOLIDATED NFOC-health: Research Group on Functional Nutrition, Oxidation and Cardiovascular Diseases

Responsible Rosa Solà Alberich CONSOLIDATED

Unitat de nutrició humana: Prevenció i Epigenètica

Responsible Jordi SALAS-SALVADÓ, Nancy BABIO SÁNCHEZ CONSOLIDATED Responsible Maria Teresa Blay Olivé ASSOCIATED

MoBioFood

SMHEALTH. Smart Health Research Group

Responsible Solanas Gómez, Agustín

ASSOCIATED



Nutrition and Metabolism

# Scientific structure of the IISPV, Areas and Groups (2/4)

#### Area 1. Nutrition & Metabolism

Pediatrics, Nutrition and Human Development Research Unit (PNHDRU)

Responsible Joaquín Escribano Subias

CONSOLIDATED

Metabolomics Interdisciplinary Lab (MiL@b)

Responsible Xavier Correig Blanchar

CONSOLIDATED

Nutrigenomics Group

Responsible Begoña Muguerza ASSOCIATED Nutrition and Mental Health Group – NUTRISAM Responsible Victoria Arija Val, Josefa Canals Sans CONSOLIDATED Biomedical Research Unit (BRU)

> Responsible Jorge Joven Maried, Jordi Camps Andreu CONSOLIDATED

Lipid and Arteriosclerosis Research Unit (LARU), and Vascular Medicine and Metabolism Unit (VMMU)

Responsible Lluís Masana Marín CONSOLIDATED

> Ophthalmology Research Group -RETIPROGRAM

Responsible Pere Romero Aroca, Domènec Puig Savi

EMERGING GROUP


Disease Biomarker and Molecular Mechanism Grup (DIBIOMEC)

Responsible Matilde Rodríguez Chacón

CONSOLIDATED

Transversal Lifestyle and Disease Prevention Program

Responsible Francisco Martín Luján



# Scientific structure of the IISPV, Areas and Groups (2/4)

#### Area 1. Nutrition & Metabolism

Pediatrics, Nutrition and Human Development Research Unit (PNHDRU)

Responsible Joaquín Escribano Subias

CONSOLIDATED

Metabolomics Interdisciplinary Lab (MiL@b)

Responsible Xavier Correig Blanchar

CONSOLIDATED

Nutrigenomics Group

Responsible Begoña Muguerza ASSOCIATED Nutrition and Mental Health Group – NUTRISAM Responsible Victoria Arija Val, Josefa Canals Sans CONSOLIDATED Biomedical Research Unit (BRU)

> Responsible Jorge Joven Maried, Jordi Camps Andreu CONSOLIDATED

Lipid and Arteriosclerosis Research Unit (LARU), and Vascular Medicine and Metabolism Unit (VMMU)

Responsible Lluís Masana Marín CONSOLIDATED

> Ophthalmology Research Group -RETIPROGRAM

Responsible Pere Romero Aroca, Domènec Puig Savi

EMERGING GROUP


Disease Biomarker and Molecular Mechanism Grup (DIBIOMEC)

Responsible Matilde Rodríguez Chacón

CONSOLIDATED

Transversal Lifestyle and Disease Prevention Program

Responsible Francisco Martín Luján



# Scientific structure of the IISPV, Areas and Groups (2/4)

#### Area 1. Nutrition & Metabolism

Pediatrics, Nutrition and Human Development Research Unit (PNHDRU)

Responsible Joaquín Escribano Subias

CONSOLIDATED

Metabolomics Interdisciplinary Lab (MiL@b)

Responsible Xavier Correig Blanchar

CONSOLIDATED

Nutrigenomics Group

Responsible Begoña Muguerza ASSOCIATED Nutrition and Mental Health Group – NUTRISAM Responsible Victoria Arija Val, Josefa Canals Sans CONSOLIDATED Biomedical Research Unit (BRU)

> Responsible Jorge Joven Maried, Jordi Camps Andreu CONSOLIDATED

Lipid and Arteriosclerosis Research Unit (LARU), and Vascular Medicine and Metabolism Unit (VMMU)

Responsible Lluís Masana Marín CONSOLIDATED

> Ophthalmology Research Group -RETIPROGRAM

Responsible Pere Romero Aroca, Domènec Puig Savi

EMERGING GROUP


Disease Biomarker and Molecular Mechanism Grup (DIBIOMEC)

Responsible Matilde Rodríguez Chacón

CONSOLIDATED

Transversal Lifestyle and Disease Prevention Program

Responsible Francisco Martín Luján



# Scientific structure of the IISPV, Areas and Groups (2/4)

#### Area 1. Nutrition & Metabolism

Pediatrics, Nutrition and Human Development Research Unit (PNHDRU)

Responsible Joaquín Escribano Subias

CONSOLIDATED

Metabolomics Interdisciplinary Lab (MiL@b)

Responsible Xavier Correig Blanchar

CONSOLIDATED

Nutrigenomics Group

Responsible Begoña Muguerza ASSOCIATED Nutrition and Mental Health Group – NUTRISAM Responsible Victoria Arija Val, Josefa Canals Sans CONSOLIDATED Biomedical Research Unit (BRU)

> Responsible Jorge Joven Maried, Jordi Camps Andreu CONSOLIDATED

Lipid and Arteriosclerosis Research Unit (LARU), and Vascular Medicine and Metabolism Unit (VMMU)

Responsible Lluís Masana Marín CONSOLIDATED

> Ophthalmology Research Group -RETIPROGRAM

Responsible Pere Romero Aroca, Domènec Puig Savi

EMERGING GROUP


Disease Biomarker and Molecular Mechanism Grup (DIBIOMEC)

Responsible Matilde Rodríguez Chacón

CONSOLIDATED

Transversal Lifestyle and Disease Prevention Program

Responsible Francisco Martín Luján



# Scientific structure of the IISPV, Areas and Groups (2/4)

#### Area 1. Nutrition & Metabolism

Pediatrics, Nutrition and Human Development Research Unit (PNHDRU)

Responsible Joaquín Escribano Subias

CONSOLIDATED

Metabolomics Interdisciplinary Lab (MiL@b)

Responsible Xavier Correig Blanchar

CONSOLIDATED

Nutrigenomics Group

Responsible Begoña Muguerza ASSOCIATED Nutrition and Mental Health Group – NUTRISAM Responsible Victoria Arija Val, Josefa Canals Sans CONSOLIDATED Biomedical Research Unit (BRU)

> Responsible Jorge Joven Maried, Jordi Camps Andreu CONSOLIDATED

Lipid and Arteriosclerosis Research Unit (LARU), and Vascular Medicine and Metabolism Unit (VMMU)

Responsible Lluís Masana Marín CONSOLIDATED

> Ophthalmology Research Group -RETIPROGRAM

Responsible Pere Romero Aroca, Domènec Puig Savi

EMERGING GROUP


Disease Biomarker and Molecular Mechanism Grup (DIBIOMEC)

Responsible Matilde Rodríguez Chacón

CONSOLIDATED

Transversal Lifestyle and Disease Prevention Program

Responsible Francisco Martín Luján



# Scientific structure of the IISPV, Areas and Groups (2/4)

#### Area 1. Nutrition & Metabolism

Pediatrics, Nutrition and Human Development Research Unit (PNHDRU)

Responsible Joaquín Escribano Subias

CONSOLIDATED

Metabolomics Interdisciplinary Lab (MiL@b)

Responsible Xavier Correig Blanchar

CONSOLIDATED

Nutrigenomics Group

Responsible Begoña Muguerza ASSOCIATED Nutrition and Mental Health Group – NUTRISAM Responsible Victoria Arija Val, Josefa Canals Sans CONSOLIDATED Biomedical Research Unit (BRU)

> Responsible Jorge Joven Maried, Jordi Camps Andreu CONSOLIDATED

Lipid and Arteriosclerosis Research Unit (LARU), and Vascular Medicine and Metabolism Unit (VMMU)

Responsible Lluís Masana Marín CONSOLIDATED

> Ophthalmology Research Group -RETIPROGRAM

Responsible Pere Romero Aroca, Domènec Puig Savi

EMERGING GROUP


Disease Biomarker and Molecular Mechanism Grup (DIBIOMEC)

Responsible Matilde Rodríguez Chacón

CONSOLIDATED

Transversal Lifestyle and Disease Prevention Program

Responsible Francisco Martín Luján



### Scientific structure of the IISPV, Areas and Groups (3/4)

#### Area 2. Health & Environment

Emergency Research Group

Responsible Youcef Azeli

EMERGING GROUP

Mycology and Environmental Microbiology -MYCOLOGY

Responsible Josep Guarro Artigas ASSOCIATED TECNATOX. Center for Environmental, Food and Toxicological Technology

> Responsible Josep Lluís Domingo, Marta Schuhmacher CONSOLIDATED

INIM. Infection and immunity

Responsible Francesc Vidal Marsal

CONSOLIDATED

#### Area 3. Neurosciences & Mental Health

GAP. Genetics and environment in Psychiatry

Responsible


Elisabet Vilella Cuadrada

CONSOLIDATED

ECOMMFIT - Experiments, Computing and Modeling in Fluid Mechanics and Turbulence

Responsible Jordi Pallarès Curto ASSOCIATED SIS. Sepsis, Inflammation and Critical Patient Safety

Responsible María Bodí, Alejandro Rodriguez Oviedo CONSOLIDATED





# Scientific structure of the IISPV, Areas and Groups (4/4)

#### Area 4. Clinical Groups

Oncology, Translational, Epidemiological and Clinical Research Group (GIOTEC)

Responsible Joan Lluís Borràs Balada, Josep Gumà Padró

ASSOCIATED

Radiotherapy Oncology Research Group

Responsible Meritxell Arenas Prat

ASSOCIATED

Otorhinolaryngological disease research group

#### Responsible Enric Figuerola Massana

ASSOCIATED

Research group on Autoimmunity, Inflammation and Infection

Responsible Antoni Castro Salomó

ASSOCIATED

Research in Oncological Pathology and Bioinformatics (PO&B)


Responsible Marylène Lejeune, Carlos López Pablo ASSOCIATED Allergology. University Hospital of Tarragona Joan XXIII

Responsible Pere Gaig Jané

ASSOCIATED


# Clinical Groups


# Material and human resources of IISPV (1/4)



IISPV has spaces dedicated to R&D in the two potential core hospitals of the Institute (JXXIII and HUSJR). There are 3,207 m<sup>2</sup> of surface area (including 260 m<sup>2</sup> for management).

# Material and human resources of IISPV (2/4)






Scientific Report 2021 (provisional)

Material and human resources of IISPV (3/4)



101 Active Projects
26 Awarded Projects
74 Active Clinical Trials
1 ISCIII Platform
6 CIBER Groups
14 Clinical practice Groups
1 Generated Innovation
1 Granted Patents
1 Granted Spin Off





8 Organised Conferences and Seminars38 Press Releases

# Material and human resources of IISPV (4/4)





Biobank IISPV



Clinical Studies Unit (CSU)



Bioinformatics



Metabolomics Platform



Histological, cytological and digitalization studies



Mental health assessment (PESaM)



Cytometry unit and cell sorting






Statistical support platform

Animal Experimentation Unit

# Interrelation of research with training and Clinical Practice in Integrated the Centres













- 01 Internal and External Analysis SWOT 02 CAME Analysis
- **03** Vision
- **04 Strategic Map**

# Internal and External Analysis

#### In order to perform the internal and external analysis, two on-line sessions were held on April 15<sup>th</sup> and June 10<sup>th</sup>, 2021

- For the Internal Analysis, the current strengths and weaknesses of the Institute were discussed. For the External Analysis, threats and opportunities were discussed.
- 44 multidisciplinary professionals participated in the first session and 56 in the second one, 52% from the first session and 48% as representatives of relevant stakeholders of the institute.
- During these sessions the addressed topics were Organization, Management, Professionals, Resources, Activities, Processes, Brand, Prestige, Leadership, Markets, Policies & Regulations, new lines of action and new initiatives.
- The SWOT summarizes the main Threats, Opportunities, Weaknesses and Strengths identified.

# Opportunities

Strengths

Weaknesses

# Consolidation of Internal and External analysis

2. 3. 4. 5. 6. 7.	<ul> <li>IISPV is a transversal and multidisciplinary institution with motivated and passionate personnel.</li> <li>IISPV is a centre that promotes synergies in biomedical research and biomedical transfer at the service of society.</li> <li>Micro-Cluster with high health knowledge and access to platforms.</li> <li>IISPV is an institution open to change and new opportunities.</li> <li>The collaboration with URV allows to maximize research activities of IISPV.</li> <li>High capacity for the management of biomedical research and innovation.</li> <li>High rate of national and international competitive public funds raised.</li> <li>IISPV as unique biomedical research hub in Tarragona area accredited by CERCA and HRS4R.</li> </ul>	wh 2. Inc inv 3. Inc 4. ISC 5. Inc 6. IRI	distence of national and international stakeholders from the health sector with hom IISPV can collaborate and learn from. creased interest in innovation and technology transfer by industry and private vestors in health. creased public funding at both national and European level. CIII accreditation as a national reference in health research. creased interest in digital transformation in the Health sector. ISCAT and ITEMAS as great opportunities for the establishment of alliances. crement of interest in R&D&I by the society due to the pandemic.
1. 2. 3. 4. 5. 6. 7. 8.	Absence of effective internal and external communication.	<ol> <li>High</li> <li>height</li> <li>Ins</li> <li>Ins<td>by perception of IISPV Brand by the Health sector and society. Igh density of other highly competitive biomedical research centres in the ealth field. sufficient R&amp;D&amp;I financing in Spain compared to other European countries. The new labour regulations are not adapted to the specificities of the research eld. Incertainty and economic crisis due to pandemic and war conflicts. sistence of other centres with higher capacity of talent retention and traction. eographical distance from the health ecosystem epicentre.</td></li></ol>	by perception of IISPV Brand by the Health sector and society. Igh density of other highly competitive biomedical research centres in the ealth field. sufficient R&D&I financing in Spain compared to other European countries. The new labour regulations are not adapted to the specificities of the research eld. Incertainty and economic crisis due to pandemic and war conflicts. sistence of other centres with higher capacity of talent retention and traction. eographical distance from the health ecosystem epicentre.

02 CAME Analysis

#### CAME Analysis: Strategic Axes

	Threats	Opportunities
	<u>Adapt</u>	<u>Explore</u>
Strengths	Achievement of a good management model in all processes and activities of the institute. Enhancement of talent attraction and retention, considering the principles of gender equality and generational turnover.	Promotion of a translational research model with an impact on the ecosystem and stakeholders in the health sector, patients and society. Dynamization of digital transformation within the institution.
	<u>Correct</u>	<u>Maintain</u>
less	Creation of an atmosphere of cooperation and cohesion between the IISPV member institutions and their professionals.	Boost IISPV internationalization.
Weakness	Provide of key tools for the development of skills and talent.	Promotion of innovation, and technological and knowledge transfer.
N	Strengthen internal and external communication.	Increase resources for IISPV through public and private funding.

IISPV's strategic plan is structured into 10 strategic axes, 22 strategic objectives and 79 activities. The definition of the strategic axes has been agreed by the members of all entities that are part from IISPV and is intended to reflect the fundamental pillars of the institute. 03 Vision


#### Vision of the IISPV Strategic Plan

#### VISION

To be a centre of reference in research, innovation and biomedical transfer at national and international level, through an efficient and sustainable model to contribute to improvements of the quality of life of patients and society.

# SANITÀRIA PERE VIRGILI

#### 04 Strategy Map: Strategic Axes



#### 04 Strategy Map: Strategic Objectives

